NCI-WG response and progression-free survival by pretreatment characteristics
| Patient characteristic . | n . | % CR . | % ORR . | Median PFS, mo . |
|---|---|---|---|---|
| Overall | 60 | 70 | 92 | 38 |
| Age, y | ||||
| < 60 | 33 | 70 | 88 | 32 |
| 61-70 | 27 | 70 | 96 | 38 |
| Sex | ||||
| Male | 45 | 64 | 89 | 32 |
| Female | 15 | 87 | 100 | 38+ |
| Rai stage | ||||
| I-II | 30 | 70 | 90 | 32 |
| III-IV | 30 | 70 | 93 | 42+ |
| ECOG PS | ||||
| 0 | 13 | 69 | 85 | 32 |
| 1-2 | 47 | 70 | 95 | 38+ |
| WBC, ×109/L | ||||
| ≤ 50 | 17 | 70 | 88 | 42+ |
| 51-150 | 25 | 72 | 92 | 32 |
| > 150 | 18 | 68 | 94 | 28 |
| β2-microglobulin, mg/L | ||||
| 4-5.0 | 26 | 69 | 96 | 38 |
| > 5.0 | 34 | 70 | 88 | 42+ |
| LDH | ||||
| < 1.5× ULN | 40 | 67 | 92 | 42+ |
| > 1.5× ULN | 20 | 75 | 90 | 32 |
| IGHV gene status | ||||
| Mutated (> 2%) | 20 | 70 | 100 | 42+ |
| Unmutated (< 2%) | 37 | 73 | 92 | 32 |
| Unavailable | 3 | 33 | 33 | 32 |
| Cytogenetics by FISH | ||||
| 17p deletion | 14 | 57* | 78* | 15* |
| 11q deletion | 10 | 80 | 90 | 27 |
| Trisomy 12 | 15 | 93 | 100 | 42+ |
| None | 10 | 50 | 90 | 42+ |
| 13q (sole) deletion | 11 | 64 | 100 | 42+ |
| CD38 expression | ||||
| ≤ 30% | 39 | 62 | 94 | 38 |
| > 30% | 21 | 86 | 90 | 28* |
| ZAP 70 (by IHC) | ||||
| Positive | 33 | 57* | 82 | 32 |
| Negative | 16 | 94 | 100 | 42+ |
| Unavailable | 11 | 73 | 91 | 38 |
| Patient characteristic . | n . | % CR . | % ORR . | Median PFS, mo . |
|---|---|---|---|---|
| Overall | 60 | 70 | 92 | 38 |
| Age, y | ||||
| < 60 | 33 | 70 | 88 | 32 |
| 61-70 | 27 | 70 | 96 | 38 |
| Sex | ||||
| Male | 45 | 64 | 89 | 32 |
| Female | 15 | 87 | 100 | 38+ |
| Rai stage | ||||
| I-II | 30 | 70 | 90 | 32 |
| III-IV | 30 | 70 | 93 | 42+ |
| ECOG PS | ||||
| 0 | 13 | 69 | 85 | 32 |
| 1-2 | 47 | 70 | 95 | 38+ |
| WBC, ×109/L | ||||
| ≤ 50 | 17 | 70 | 88 | 42+ |
| 51-150 | 25 | 72 | 92 | 32 |
| > 150 | 18 | 68 | 94 | 28 |
| β2-microglobulin, mg/L | ||||
| 4-5.0 | 26 | 69 | 96 | 38 |
| > 5.0 | 34 | 70 | 88 | 42+ |
| LDH | ||||
| < 1.5× ULN | 40 | 67 | 92 | 42+ |
| > 1.5× ULN | 20 | 75 | 90 | 32 |
| IGHV gene status | ||||
| Mutated (> 2%) | 20 | 70 | 100 | 42+ |
| Unmutated (< 2%) | 37 | 73 | 92 | 32 |
| Unavailable | 3 | 33 | 33 | 32 |
| Cytogenetics by FISH | ||||
| 17p deletion | 14 | 57* | 78* | 15* |
| 11q deletion | 10 | 80 | 90 | 27 |
| Trisomy 12 | 15 | 93 | 100 | 42+ |
| None | 10 | 50 | 90 | 42+ |
| 13q (sole) deletion | 11 | 64 | 100 | 42+ |
| CD38 expression | ||||
| ≤ 30% | 39 | 62 | 94 | 38 |
| > 30% | 21 | 86 | 90 | 28* |
| ZAP 70 (by IHC) | ||||
| Positive | 33 | 57* | 82 | 32 |
| Negative | 16 | 94 | 100 | 42+ |
| Unavailable | 11 | 73 | 91 | 38 |
P < .05.
NCI-WG indicates National Cancer Institute–Working Group; CR, complete remission; ORR, overall response rate; PFS, progression-free survival; ECOG, Eastern Cooperative Oncology Group; PS, performance status; LDH, lactate dehydrogenase; IHC, immunohistochemistry; ULN, upper limit of normal; and +, median not reached.